NCT06736379 - Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 13, 2025

Primary Completion Date

March 30, 2027

Study Completion Date

May 30, 2027

Conditions

Head and Neck Cancers- Squamous CellHead and Neck CancerSolid TumorsHNSCCSCC - Squamous Cell CarcinomaSCCHNHead Neck CancerHead and Neck Squamous Cell CancerSquamous Cell Carcinoma of the Head and NeckSquamous Cell Carcinoma, Head And NeckSquamous Cell Head and Neck CarcinomaOral CavityOral Cavity Carcinoma

Interventions

BIOLOGICAL

VRP-encapsulated saRNA encoding IL-12 (1 x 10^9 viral particles per injection)

Weekly IT injections of 1 x 10\^9 viral particles of VLPONC-01

DRUG

Pembrolizumab (KEYTRUDA®)

200mg twice 3 weeks apart IV

BIOLOGICAL

VRP-encapsulated saRNA encoding IL-12 (3 x 10^8 viral particles per injection)

Weekly IT injections of 3 x 10\^8 viral particles of VLPONC-01

Trial Locations (1)

34305

RECRUITING

Stanford University, Stanford